Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RAMM PharmaXCNQ:RAMM Debt-to-Equity is 0.01 as of Apr. 2026, which is at its 10-year median of 0.01. The stock has 4 warning signs investors should review. Among 813 Drug Manufacturers companies, RAMM Pharma ranks better than 99.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for RAMM Pharma's Debt-to-Equity or its related term are showing as below:
XCNQ:RAMM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -23.12 Med: 0.01 Max: 0.06
Current: 0.01
During the past 8 years, the highest Debt-to-Equity Ratio of RAMM Pharma was 0.06. The lowest was -23.12. And the median was 0.01.
XCNQ:RAMM's Debt-to-Equity is ranked better than 99.88% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs XCNQ:RAMM: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
RAMM Pharma Debt-to-Equity Related Terms
RAMM Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a Debt-to-Equity of 0.01 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on RAMM Pharma and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, RAMM Pharma ranks #1 out of 813 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is RAMM Pharma's Debt-to-Equity too high?
RAMM Pharma's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.27. RAMM Pharma's value of 0.01 is 96.3% below this industry median. Based on the distribution chart, RAMM Pharma ranks #1 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does RAMM Pharma's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #1 out of 813 companies for Debt-to-Equity. This places RAMM Pharma in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. RAMM Pharma's value of 0.01 is 96.3% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.27, RAMM Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RAMM Pharma's current Debt-to-Equity of 0.01 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 96.3% below the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Debt-to-Equity is 0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 
